Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily LLY Bull 2X Shares

26.99
-0.3761-1.37%
Post-market: 26.90-0.0904-0.33%19:58 EDT
Volume:44.38K
Turnover:1.20M
Market Cap:16.87M
PE:- -
High:27.84
Open:27.46
Low:26.54
Close:27.37
52wk High:35.13
52wk Low:16.34
Shares:625.00K
Float Shares:625.00K
Volume Ratio:0.72
T/O Rate:7.10%
Dividend:3.16
Dividend Rate:11.71%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Novartis Bets $7.8 Billion On MRNA Beyond Vaccines

Options & Short Sell
·
Yesterday

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

TIPRANKS
·
5 hours ago

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
12 hours ago

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
12 hours ago

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
12 hours ago

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
12 hours ago

Correction: Top Midday Decliners

MT Newswires Live
·
Yesterday

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Yesterday

Sector Update: Healthcare

MT Newswires Live
·
Yesterday

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
Yesterday

Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says

MT Newswires Live
·
Yesterday

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Oct 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 01

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Oct 01

Lilly Says Foundayo Cuts Predicted 10-Year Type 2 Diabetes Risk 57% in Attain-1 Post-Hoc Analysis

Reuters
·
Oct 01

Eli Lilly - Foundayo 17.2 Mg Associated with 57% Reduction in Diabetes Risk, 18% in Cardiovascular Risk Versus Placebo

Reuters
·
Oct 01

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Oct 01

23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?

Options & Short Sell
·
Oct 01

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
Oct 01